Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$46.72
+1.6%
$38.37
$21.72
$46.70
$8.86B1.152.52 million shs34,244 shs
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$6.51
-1.2%
$5.39
$3.96
$9.85
$2.42B0.412.60 million shs33,722 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.77
-0.1%
$13.24
$8.02
$15.78
$7.32B1.675.05 million shs36,935 shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$104.85
+0.1%
$82.60
$16.91
$104.95
$8.51B0.241.53 million shs2.21 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+6.46%+7.35%+17.81%+42.31%+78.91%
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-1.79%-7.31%+35.04%+51.32%-8.41%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+0.34%+0.48%+6.17%+70.06%+9.10%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
+20.62%+16.31%+23.78%+94.27%+514.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.6926 of 5 stars
4.52.00.03.92.43.30.6
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
3.6927 of 5 stars
1.93.00.04.02.33.30.6
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.3877 of 5 stars
1.34.00.00.31.91.71.3
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.7666 of 5 stars
2.41.00.00.03.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
3.00
Buy$58.9326.14% Upside
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
1.83
Reduce$7.3012.07% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.50
Moderate Buy$15.333.81% Upside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.83
Moderate Buy$110.275.17% Upside

Current Analyst Ratings Breakdown

Latest BHC, BBIO, ELAN, and VRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$138.00 ➝ $107.00
7/10/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/9/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$60.00
7/9/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$107.00
7/9/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$140.00 ➝ $107.00
7/2/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $17.00
7/1/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$170.00
6/30/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$67.00 ➝ $76.00
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/25/2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $54.00
6/23/2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$76.00 ➝ $160.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$127.42M69.62N/AN/A($7.71) per share-6.06
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$9.73B0.25$7.49 per share0.87($0.89) per share-7.32
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.66$2.26 per share6.55$12.33 per share1.20
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$118.54M71.72N/AN/A$2.56 per share40.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$535.76M-$3.53N/AN/AN/A-524.25%N/A-94.43%7/30/2025 (Estimated)
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
-$46M-$0.11N/A1.40N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7419.9316.602.888.43%7.54%3.57%8/6/2025 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$2.00N/A3,494.93N/AN/A-69.65%-28.00%8/6/2025 (Estimated)

Latest BHC, BBIO, ELAN, and VRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.50N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$0.39N/AN/AN/A$68.24 millionN/A
7/30/2025Q2 2025
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
$0.9320N/AN/AN/A$2.47 billionN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
4/29/2025Q1 2025
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$1.00-$0.88+$0.12-$0.88$57.14 million$36.74 million
4/29/2025Q1 2025
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
4.57
4.54
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
N/A
1.35
0.97
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
1.07
8.86
8.73
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400189.88 million155.32 millionOptionable
Bausch Health Cos Inc. stock logo
BHC
Bausch Health Cos
20,700370.08 million340.29 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3081.08 million81.05 millionOptionable

Recent News About These Companies

Verona Pharma leaps on news of Merck & Co takeover bid
Merck confirms $10B buyout of Verona Pharma
Top Mid Cap Stocks To Add to Your Watchlist - July 9th
Promising Pharmaceutical Stocks To Watch Now - July 9th
Top Medical Stocks Worth Watching - July 9th
Merck to Buy Verona Pharma in $10 Billion Deal
Merck to acquire Verona Pharma for $10 billion

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$46.72 +0.74 (+1.60%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Bausch Health Cos stock logo

Bausch Health Cos NYSE:BHC

$6.51 -0.08 (-1.15%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.77 -0.01 (-0.06%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$104.85 +0.08 (+0.07%)
As of 09:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.